Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Medical Developments International Limited (MDIL) specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company's operations are divided into two primary segments: Pain Management and Respiratory care. Among its key offerings is Penthrox, a product specifically formulated for rapid pain relief in acute trauma and emergency situations. Within the respiratory segment, MDIL supplies equipment designed to assist individuals with conditions like asthma and chronic obstructive pulmonary disease (COPD). Additionally, its comprehensive portfolio features a diverse array of medical devices, encompassing items such as CPR face shields and masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, oxygen resuscitation kits, and various oxygen therapy and resuscitation apparatus. Established in 2003, the company maintains its headquarters in Scoresby, Australia.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, und
Target Price
The average target price of MVP.AX is 1.96 and suggests 351% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc